WINDLAS Windlas Biotech Q1 FY27 results (Apr–Jun 2026) and concall
Windlas Biotech Limited delivered a strong Q1 FY27 with record revenue of INR 248 crores, up 18% YoY, and robust profit growth driven by its CDMO and Exports segments. The company completed a buyback and declared a dividend, while progressing with Plant 6 commercialization. Challenges in the Trade Generics segment due to product discontinuation and ongoing API price volatility were noted, but management remains confident in long-term growth strategies.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed before this quarter
Q4 FY26: revenue up 17.2%, net profit up 0.0% against the same quarter last year.
| Line item | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 175 | 187 | 195 | 203 | 210 +20% | 222 +19% | 233 +19% | 238 +17% |
| EBITDA | 21 | 23 | 25 | 26 | 27 +29% | 29 +26% | 24 −4% | 25 −4% |
| Net profit | 13 | 16 | 16 | 16 | 18 +38% | 18 +13% | 15 −6% | 16 +0% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
